Menu
Platform Technologies
Brain Disease
Cancer Therapy
Brain Delivery Platform
Summary
• Small-sized (30 nm) and ligand-free MSNs with high surface PEGylation and optimized properties are capable of crossing the blood–brain barrier (BBB).
• The MSN platform enables delivery of hydrophilic and hydrophobic drugs across the BBB for treating brain diseases.
• MSN technology allows for the customization of particle and pore sizes, drug loading, and surface attributes, making it versatile for various medical uses.
BBB Penetration Ability
• NTT’s MSNs have demonstrated the ability to cross the BBB in both an in vitro BBB model and in vivo animal studies.
• MSN penetration across the BBB is mediated by serum protein adsorption, primarily albumin, kininogen, and apolipoproteins (especially ApoE), enabling receptor- and adsorptive-mediated transcytosis and potentially modulating tight junction permeability via the paracellular pathway.
• The protein corona is enriched with ApoE, a key protein involved in lipid transport into the brain. Given the higher lipid demand of the human brain compared to mice, this approach holds strong translational potential for human applications.
Further details can be found in our publication: ACS Nano 2024, 18, 12716